Immunomodulatory treatment approaches for prostate cancer;Immunmodulatorische Therapieansätze beim Prostatakarzinom

Urologe - Ausgabe A

Volumn 48, Issue 7, 2009, Pages 755-763

  Reiter, M A ^a   Pfitzenmaier, J ^a   Hohenfellner, M ^a   Haferkamp, A ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Cancer vaccines; Dendritic cells; Immunotherapy; Prostate cancer

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA INTERFERON; BCG VACCINE; BISPHOSPHONIC ACID DERIVATIVE; CYTOKINE; DOCETAXEL; FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMORAL ANTIBODY; HYDROCORTISONE; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 2; KETOCONAZOLE; NILUTAMIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; CANCER CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; COMPLEMENT SYSTEM; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; INNATE IMMUNITY; MACROPHAGE; MAST CELL; MEDIATOR; MEDICAL LITERATURE; MEDLINE; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL; PROSTATE CANCER; REVIEW; SYSTEMATIC REVIEW; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; CANCER VACCINES; HUMANS; IMMUNOLOGIC FACTORS; MALE; PROSTATIC NEOPLASMS;

EID: 68349150907     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-009-1984-6     Document Type: Review

References (62)

1. Ferlay J, Autier P, Boniol M et al (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18(3): 581-592
2. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics. CA cancer J Clin 58(2): 71 -96
3. Pound CR, Partin AW, Eisenberger MA et al (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (17): 1591-1597
4. Maximum androgen blockade in advanced prostate cancer (1995) an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists Collaborative Group. Lancet 346(8970): 265-269
5. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantroneand prednisone for advanced refractory prostate cancer. N Engl J Med 351 (15): 1513-1520
6. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15): 1502-1512
7. Pollard M, Luckert PH (1993) The anti-metastatic effect of intravenously-inoculated BCG on prostate tumor cells. Anticancer Res 13(3): 705-708
8. Pollard M, Luckert PH (1994) The antimetastatic effect of IV-inoculated BCG on adenocarcinomas in the prostate-seminal vesicle complex of L-W rats. Anticancer Res 14(3A): 901-903
9. Guiñan PToronchi E, Shaw M et al (1982) Bacillus calmette-guerin (BCG) adjuvant therapy in stage D prostate cancer. Urology 20(4): 401-403
10. Guinan PD, John T, Nagale V, Ablin RJ (1978) BCG adjuvant immunotherapy in carcinoma of the prostate: an interim report. Allergol lmmunopathol (Madr) 6(4): 293-296
11. Robinson MR, Rigby CC, Pugh RC, Dumonde DC (1977) Adjuvant immunotherapy with B.C.G. in carcinoma of the prostate. Br J Urol 49(3): 221-226
12. Robinson MR, Rigby CC, Pugh RC, Dumonde DC (1978) Prostate carcinoma: intratumor BCG immunotherapy. J Natl Cancer Inst Monogr 49:351-353
13. Hrouda D, Souberbielle BE, Kayaga J et al (1998) Mycobacterium vaccae (SRL172): a potential immunological adjuvant evaluated in rat prostate cancer. Br J Urol 82(6): 870-876
14. Hrouda D, Baban B, Dunsmuir WD et al (1998) Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). Br J Urol 82(4): 568-573
15. Krejci KG, Markiewicz MA, Kwon ED (2004) Immunotherapy for urological malignancies. J Urol 171(2 Pt 1): 870-876
16. Heinzer H, Huland E, Huland H (2001) Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer. World J Urol 19(2): 111-119
17. Hautmann SH, Huland E, Huland H (1999) Local intratumor immunotherapy of prostate cancer with interleukin-2 reduces tumor growth. Anticancer Res 19(4A): 2661-2663
18. Kocheril SV, Grignon DJ, Wang CY et al (1999) Responsiveness of human prostate carcinoma bone tumors to interleukin-2 therapy in a mousexenograft tumor model. Cancer Detect Prev 23(5): 408416
19. Dieli F, Vermijlen D, Fulfaro F et al (2007) Targeting human gamma delta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67(15): 7450-7457
20. Maffezzini M, Simonato A, Fortis C (1996) Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rlL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing secondline hormonal treatment. Prostate 28(5): 282-286
21. DranoffGJaffeeE,LazenbyAetal(1993)Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90(8): 3539-3543
22. Dreicer R, See WA, Klein EA (2001 ) Phase II trial of GM-CSF in advanced prostate cancer. Invest New Drugs 19(3): 261-265
23. Small EJ, Reese DM, Um B et al (1999) Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 5(7): 1738-1744
24. Rini BI, Weinberg V, Bok R, Small EJ (2003) Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colonystimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol 21(1): 99-105
25. Rini BI, Fong L, Weinberg Vet al (2006) Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocytemacrophage colony-stimulating factor. J Urol 175(6): 2087-2091
26. Ryan CJ, Weinberg V, Rosenberg J et al (2007) Phase II study of ketoconazole plus granulocytemacrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome. J Urol 178(6): 2372-2376
27. Dreicer R, Klein EA, Elson P et al (2005) Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer. Urol Oncol 23(2): 82-86
28. Kramer G, Steiner GE, Sokol P et al (2001 ) Local intratumoral tumor necrosis factor-alpha and systemic IFN-alpha 2b in patients with locally advanced prostate cancer. J Interferon Cytokine Res 21(7): 475-484
29. Kiessling A, Fussel S, Wehner R et al (2008) Advances in specific immunotherapy for prostate cancer. Eur Urol 53(4): 694-708
30. Noguchi M, ltoh K, Yao A et al (2005) Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. Prostate 63(1): 1-12
31. Gates JD, Carmichael MG, Benavides LC et al (2009) Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients. J Am Coll Surg 208(2): 193-201
32. Eder JP, Kantoff PW, Roper K et al (2000) A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 6(5): 1632-1638
33. Gulley J, Chen AP, Dahut W et al (2002) Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 53(2): 109-117
34. Kaufman HL, Wang W, Manola J et al (2004) Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 22(11): 2122-2132
35. Arlen PM, Gulley JL, Parker C et al (2006) A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12(4): 1260-1269
36. Amato RJ, Drury N, Naylor S et al (2008) Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J lmmunother 31 (6): 577-585
37. Madan RA, Gulley JL, Schlom J et al (2008) Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide and combination therapy. Clin Cancer Res 14(14): 4526̌1531
38. Pavlenko M, Roos AK, Lundqvist A et al (2004) A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 91(4): 688-694
39. Simons JW, Carducci MA, Mikhak B et al (2006) Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res 12(11 Pt 1): 3394-3401
40. Urba WJ, Nemunaitis J, Marshall F et al (2008) Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. J Urol 180(5): 2011-2017
41. Small EJ, Sacks N, Nemunaitis J et al (2007) Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 13(13): 3883-3891
42. Higano CS, Corman JM, Smith DC et al (2008) Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113(5): 975-984
43. Steinman RM (2003) Some interfaces of dendritic cell biology. Apmis 111 (7-8): 675-697
44. Hsu FJ, Benike C, Fagnoni F et al (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2(1): 52-58
45. Nestle FO, AlijagicS,Gilliet Metal (1998)Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4(3): 328-332
46. Murphy G, Tjoa B, Ragde H et al (1996) Phase I clinical trial:T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201specific peptides from prostate-specific membrane antigen. Prostate 29(6): 371 -380
47. Tjoa BA, Erickson SJ, Bowes VA et al (1997) Followup evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 32(4): 272-278
48. Tjoa BA, Simmons SJ, Bowes VA et al (1998) Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36(1): 39-44
49. Waeckerle-Men Y, Uetz-von Allmen E, Fopp M et al (2006) Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol lmmunother 55(12): 1524-1533
50. Barrou B, Benoit G, Ouldkaci M et al (2004) Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol lmmunother 53(5): 453-460
51. Heiser A, Coleman D, Dannull J et al (2002) Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109(3): 409-417
52. Su Z, Dannull J, Yang BK et al (2005) Telomera-se mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 174(6): 3798-3807
53. Small EJ, Fratesi P, Reese DM et al (2000) Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18(23): 3894-3903
54. Small EJ, Schellhammer PF, Higano CS et al (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24(19): 3089-3094
55. Milowsky Ml, Nanus DM, Kostakoglu L et al (2004) Phase I trial of yttrium-90-labeled anti-prostatespecific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 22(13): 2522-2531
56. Bander NH, Milowsky Ml, Nanus DM et al (2005) Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23(21): 4591-4601
57. Galsky MD, Eisenberger M, Moore-Cooper S et al (2008) Phase I trial of the prostate-specific membrane antigen-directed immunoconjuga-te MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol 26(13):2147-2154
58. Lara PN Jr, Chee KG, Longmate J et al (2004) Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 100(10): 2125-2131
59. Slovin SF, Scher HI, Divgi CR et al (1998) lnterferon-gamma and monoclonal antibody 1311-labeled CC49: outcomes in patients with androgen-independent prostate cancer. Clin Cancer Res 4(3): 643-651
60. Di Lorenzo G, Figg WD, Fossa SD et al (2008) Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 54(5): 1089-1094
61. Fong L, Kwek SS, O'Brien S et al (2009) Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 69(2): 609-615
62. Emerson L, Morales A (2009) lntralesional recombinant alpha-interferon localised prostate cancer: a pilot study with follow-up of 10 years. BJU (epub ahead)